169 related articles for article (PubMed ID: 2259919)
1. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
[TBL] [Abstract][Full Text] [Related]
2. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474
[TBL] [Abstract][Full Text] [Related]
3. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Enschede SH; Porter C; Venugopal P; Gregory SA
Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
[TBL] [Abstract][Full Text] [Related]
7. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
[No Abstract] [Full Text] [Related]
8. Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma.
Yau JC; Germond C; Gluck S; Cripps C; Verma S; Burns BF; Koski TM; Lister DC; Goss GD
Am J Hematol; 1998 Oct; 59(2):156-60. PubMed ID: 9766801
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S
J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
11. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
[TBL] [Abstract][Full Text] [Related]
12. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK
Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972
[TBL] [Abstract][Full Text] [Related]
14. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
15. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S
Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302
[No Abstract] [Full Text] [Related]
17. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.
Landys KE
Invest New Drugs; 1988 Jun; 6(2):105-13. PubMed ID: 3170130
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Ho AD; del Valle F; Rückle H; Schwammborn J; Schlimok G; Hiddemann W; Meusers P; Thiel E; Dörken B; Hunstein W
Cancer; 1989 Oct; 64(7):1388-92. PubMed ID: 2776103
[TBL] [Abstract][Full Text] [Related]
20. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Unterhalt M; Herrmann R; Wöltjen HH; Kreuser ED; Trümper L; Reuss-Borst M; Terhardt-Kasten E; Busch M; Neubauer A; Kaiser U; Hanrath RD; Middeke H; Helm G; Freund M; Stein H; Tiemann M; Parwaresch R
J Clin Oncol; 1998 May; 16(5):1922-30. PubMed ID: 9586911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]